Evidence map›Paper›PMID 37359405›Full record

ArticleHealth science reports2023

How can we deliver on the promise of precision medicine in oncology and beyond? A practical roadmap for action.

Anne-Marie Baird, C Benedikt Westphalen, Sandra Blum, Begonya Nafria, Tanya Knott, Ify Sargeant, Helena Harnik, Nicholas Brooke, Nicole Wicki, Durhane Wong-Rieger

Open access · goldAbstract read
In one paragraph

Article in Health science reports, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed, 1 pooled it
6.5field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

14 citing papers in PubMed, 1 synthesis or guideline pooled it, 27 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Article
  4. Review
  5. Global Health and Genomics.The Nursing clinics of North America · 2025
    Review
  6. Article
  7. Review
  8. Review
  9. Article
  10. Article
  11. Review
  12. Article
  13. Article
  14. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 7 institutions in 6 countries.

Anne-Marie BairdLung Cancer Europe (LuCE) Bern Switzerland.
C Benedikt WestphalenComprehensive Cancer Center Munich and Department of Medicine III University Hospital, LMU Munich Munich Germany.
Sandra BlumFrom Testing to Targeted Treatments (FT3) Program Team, The Synergist Brussels Belgium.
Begonya NafriaFrom Testing to Targeted Treatments (FT3) Program Team, The Synergist Brussels Belgium.
Tanya KnottFrom Testing to Targeted Treatments (FT3) Program Team, The Synergist Brussels Belgium.
Ify SargeantTwist Medical Burlingame California USA.
Helena HarnikFrom Testing to Targeted Treatments (FT3) Program Team, The Synergist Brussels Belgium.ORCID 0000-0001-6690-1459
Nicholas BrookeFrom Testing to Targeted Treatments (FT3) Program Team, The Synergist Brussels Belgium.
Nicole WickiFrom Testing to Targeted Treatments (FT3) Program Team, The Synergist Brussels Belgium.
Durhane Wong-RiegerFrom Testing to Targeted Treatments (FT3) Program Team, The Synergist Brussels Belgium.
Synergetics (Belgium) · BECollaborative Drug Discovery (United States) · USHospital Sant Joan de Déu Barcelona · ESLMU Klinikum · DERoche (Switzerland) · CHScience Foundation Ireland · IESwiss Cancer League · CH

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Precision medicine (PM) is a form of personalized medicine that recognizes that individuals with the same condition may have different underlying factors and uses molecular information to provide tailored treatments. This approach can improve treatment outcomes and transform lives through favorable risk/benefit ratios, avoidance of ineffective interventions, and possible cost savings, as evidenced in the field of lung cancer and other oncology/therapeutic settings, including cardiac disease, diabetes, and rare diseases. However, the potential benefits of PM have yet to be fully realized. Discussion: There are many barriers to the implementation of PM in clinical practice, including fragmentation of the PM landscape, siloed approaches to address shared challenges, unwarranted variation in availability and access to PM, lack of standardization, and limited understanding of patients' experience and needs throughout the PM pathway. We believe that a diverse, intersectoral multistakeholder collaboration, with three main pillars of activity: generation of data to demonstrate the benefit of PM, education to support informed decision-making, and addressing barriers across the patient pathway, is necessary to reach the shared goal of making PM an accessible and sustainable reality. Besides healthcare providers, researchers, policymakers/regulators/payers, and industry representatives, patients in particular must be equal partners and should be central to the PM approach-from early research through to clinical trials and approval of new treatments-to ensure it represents their entire experience and identifies barriers, solutions, and opportunities at the point of delivery. Conclusion: We propose a practical and iterative roadmap to advance PM and call for all stakeholders across the healthcare system to employ a collaborative, cocreated, patient-centered methodology to close gaps and fully realize the potential of PM.

Indexed as

collaborative precision medicineequitable access precision medicinepatient engagementprecision medicine

Identifiers

PMID37359405
PMCPMC10286856
OpenAlexW4381848536

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.